Valneva reports positive six-month antibody persistence and safety phase 2 results in children for its single-shot chikungunya vaccine ixchiq®

Saint-herblain (france), june 5, 2025 – valneva se (nasdaq: valn; euronext paris: vla), a specialty vaccine company, today announced positive six-month antibody persistence and safety data for its phase 2 clinical trial evaluating the safety and immunogenicity of two different dose levels of its single-shot chikungunya vaccine, ixchiq®, in 304 children. partially funded by the coalition for epidemic preparedness innovations (cepi), with support from the european union, the trial is intended to support a pivotal phase 3 study in children, which the company expects to initiate in the first quarter of 2026, with the objective of extending the product label to this age group.
VALN Ratings Summary
VALN Quant Ranking